臨床前CRO公司美迪西6月資訊總結(jié)：美迪西榮獲“最佳賦能服務(wù)機(jī)構(gòu)”獎(jiǎng)（臨床前CRO），再度入選2025中國醫(yī)藥CRO企業(yè)20強(qiáng)，并被評為浦東新區(qū)首批“出海先鋒企業(yè)”。

The compound was synthesized for Cerepeut Inc. by the Chemistry Branch of Medicilon.

Part of the compound synthesis was performed at Medicilon.

BAY-1834845 and PF-06650833 are synthesize by Medicilon.

Pharmacokinetics, toxicokinetics and anti-drug antibodies of YYB-101 in cynomolgus monkeys were conducted by the Test and Control Article Department of Medicilon Preclinical Research, LLC, in accordance with regulations outlined in the USDA Animal Welfare

Pharmacokinetic studies in mice for L-4FPG, L-4OHPG, and L-4ClPG were performed by Medicilon.

CDX studies were performed at Shanghai Medicilon (OS-RC-2). All studies were performed in accordance with animal research guidelines from the Shanghai Medicilon Inc.

Pharmacokinetic studies performed by Medicilon.

Dolutegravir (DTG) sodium salt and free base were provided by Medicilon.

Recombinant proteins were synthesized and purified by Medicilon

The experiments (Rat colon distension model of IBS-d) were carried out by Medicilon. The protocol complied with and was approved by the Institutional Animal Care and Use Committee and Medicilon is accredited by the NIH Office of laboratory Animal Welfare

Butenolide with a purity >99% was synthesized by Medicilon.

Ocular Pharmacokinetic studies were performed at Medicilon.

Pharmacokinetic studies were performed by Shanghai Medicilon Inc, China, following standard protocols.

MGST1 and ATG16L1 overexpression, and MGST1 depletion assay were conducted by Medicilon.

The flowcytometry (FCM)-based immune profiling panel studies in J558 allograft syngeneic mouse models were performed at Medicilon. In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies w

CRO公司美迪西2025年4月公司新聞與市場活動(dòng)合集：美迪西順利通過FDA現(xiàn)場復(fù)查，其國際研發(fā)實(shí)力再獲認(rèn)可；美迪西榮膺“2025中國CRO卓越品牌榜企業(yè)20強(qiáng)”；美迪西ELU42 IND申報(bào)團(tuán)隊(duì)榮獲Eluciderm“卓越服務(wù)獎(jiǎng)”。

美迪西2025年4月公司新聞與市場活動(dòng)合集：美迪西任命葛建博士為臨床前研究事業(yè)部執(zhí)行副總裁、浦東新區(qū)人大常委會(huì)副主任倪倩帶隊(duì)調(diào)研上海美迪西生物醫(yī)藥股份有限公司張江園區(qū)，實(shí)地考察美迪西實(shí)驗(yàn)室并召開座談會(huì)。

加入我們，共同見證：Medicilon USA(波士頓)盛大開業(yè)這是我們推動(dòng)新藥創(chuàng)新加速藥物研發(fā)使命的新步伐！

雜質(zhì)結(jié)構(gòu)的鑒定與解析是確保藥品安全性和有效性的核心環(huán)節(jié)。不充分的雜質(zhì)研究可能引發(fā)藥品安全性和有效性的風(fēng)險(xiǎn)，因此，科研人員和生物醫(yī)藥企業(yè)必須通過一系列試驗(yàn)來確保雜質(zhì)得到有效的控制和管理。美迪西云講堂邀請工藝分析部吳藝嵐和大家一起探討雜質(zhì)結(jié)構(gòu)解析的最新進(jìn)展，為大家解答如何優(yōu)化試驗(yàn)操作。點(diǎn)擊鏈接“http://www.7080m.com/video/impurity-identifica